

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

GROUP: 1614

Atsushi MIWA, et al.

SERIAL NO: 10/533,081

EXAMINER: THOMAS, TIMOTHY P.

FILED: November 9, 2006

FOR: QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES
INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL
COMPOSITIONS CONTAINING THE SAME

RESTRICTION RESPONSE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated October 30, 2008, Applicants elect, without traverse, Group I, Claims 40 and 51-53 (drawn to a compound/composition comprising a compound), for examination.

Applicants also provisionally elect, without traverse and for examination purposes only, the following specie of compound: 1-(2-cyclohexyl-ethyl)-3-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-urea (compound No. 16 on page 50 of the specification) (claims 51-53 readable thereon).

Remarks/Arguments begin on page 2 of this paper.